The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?
In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years.
“Five years after the initial accelerated approval, you should have a definitive answer,” said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not.”
The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs.
It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce better evidence before gaining full approval.
Related articles:
Related suggestion:
Alabama state senator chides male colleagues for letting parental leave bill dieForget five a day... you need to eat 30 plants a week! Here HUGH FEARNLEYTSA discovers bag of snakes in passenger's pants at Miami airportMcGlynn scores in second half, helps Union earn 2Juro Kara, rebel playwright behind Japan's modern underground theater, dies at 84Quick start sends Earthquakes to 3Georgian protesters against 'RussiaSuárez has strong 6Georgian protesters against 'RussiaFratkin rallies Boston to 4
2.6373s , 6498.8046875 kb
Copyright © 2024 Powered by Study: Many cancer drugs unproven 5 years after accelerated approval ,Earthly Echo news portal